Advertisement
Canadian Journal of Cardiology

EVALUATION OF THE REAL-WORLD PLACE OF THE ICOSAPENT ETHYL (IPE) FOR THE TREATMENT OF PATIENTS WITH HYPERTRIGLYCERIDEMIA REQUIRING INVASIVE CORONARY ANGIOGRAM

      Background

      Although the REDUCE-IT trial recently demonstrated the benefits of Icosapent ethyl (IPE) on reducing ischemic events in a broad population of primary and secondary prevention patients with hypertriglyceridemia, its generalizability to patients referred for a coronary angiogram is not known yet. This study aims to determine the proportion of patients referred for a coronary angiogram that would be eligible for IPE treatment.

      Methods and Results

      In this prospective study, all patients referred to the catheterization laboratory in a tertiary academic center between January 1st, 2022 and February 15th, 2022 were enrolled. Patients meeting the inclusion criteria of the REDUCE-IT trial were included. A total of 350 patients were screened and included in our study. The average age was 68±11 and 64% were males. Hypertension and diabetes were present in 76% and 40% of patients, respectively. A total of 253 patients (72.3%) had dyslipidemia. The mean left ventricular ejection fraction (LVEF) was 52±14%. A lipid profile was available in 73% of cases in the 6 months preceding the procedure. A total of 38 patients (16.2%) referred to the catheterization laboratory currently on statin therapy would be eligible for IPE, according to REDUCE-IT criteria. No difference was found between patients with acute coronary syndrome and chronic coronary syndrome in terms of elibility for IPE treatment (13.5% vs 21.8%, p=0.132). No eligible patient was yet started on IPE.

      Conclusion

      These analyses would support IPE usage as an adjunct to secondary prevention therapies in eligible patients referred for a coronary angiogram. Findings of this study need to be confirmed in larger scale cohorts.